The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
NMR-based screening in drug discovery
Abstract
1. Introduction 211 2. Screening methods 213 2.1 Chemical shifts 213 2.2 Diffusion 214 2.3 Transverse relaxation 218 2.4 Nuclear Overhauser effects 218 3. Strategies for drug discovery and design 221 3.1 Fragment-based methods 221 3.1.1 Linked-fragment approach 221 3.1.2 Directed combinatorial libraries 222 3.1.3 Modification of high-affinity ligands 223 3.1.4 Solvent mapping techniques 223 3.2 High-throughput NMR-based screening 224 3.3 Enzymatic assays 226 4. Discovery of novel ligands 227 4.1 High-affinity ligands for FKBP 227 4.2 Potent inhibitors of stromelysin 229 4.3 Ligands for the DNA-binding domain of the E2 protein 233 4.4 Discovery of Erm methyltransferase inhibitors 233 4.5 Phosphotyrosine mimetics for SH2 domains 236 5. Conclusions 237 6. References 237 A critical step in the drug discovery process is the identification of high-affinity ligands for macromolecular targets. Traditionally, the identification of such lead compounds has been accomplished through the high-throughout screening (HTS) of corporate compound repositories. Conventional HTS methodology has enjoyed widespread application and success in the pharmaceutical industry and, through recent technological advances in screening (Fernandes, 1998; Oldenburg et al. 1998; Silverman et al. 1998) and combinatorial chemistry (Fauchere et al. 1998; Fecik et al. 1998), these programs will continue to have a prominent role in drug discovery. However, suitable leads cannot always be found using conventional methods. This is not surprising since typical corporate libraries contain fewer than 10 6 compounds compared with the estimated 10 50–10 80 universe of compounds (Martin, 1997). In addition, most conventional assays are limited to screening libraries of compounds against proteins with known function, excluding the large number of targets becoming available from genomics research. Recently, a number of NMR-based screening methods have been employed to identify and design lead ligands for protein targets (see Table 1). These NMR-based strategies can augment ongoing conventional HTS for identifying leads and can be used to aid in lead optimization. All of these techniques take advantage of the fact that upon complex formation between a target molecule and a ligand, significant perturbations can be observed in NMR-sensitive parameters of either the target or the ligand. These perturbations can be used qualitatively to detect ligand binding or quantitatively to assess the strength of the binding interaction. In addition, some of the techniques allow the identification of the ligand binding site or which part of the ligand is responsible for interacting with the target. In this article, the current state of NMR-based screening is reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Technological advances in high-throughput screening
Fernandes, P. B. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80089-6 · Cited by 170
New assay technologies for high-throughput screening
Silverman, L., Campbell, R., & Broach, J. R. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80015-x · Cited by 151
Cited by
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Cohen, Y., Avram, L., & Frish, L. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200300637 · Cited by 1,122
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Self-citationNMR Spectroscopy Techniques for Screening and Identifying Ligand Binding to Protein Receptors
Meyer, B., & Peters, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390233 · Cited by 1,039
Metadata
- Authors
- Hajduk, P. J., Meadows, R. P., & Fesik, S. W.
- Venue
- Quarterly Reviews of Biophysics
- Publisher
- Cambridge University Press (CUP)
- Published
- 1999-08
- Volume
- 32
- Issue
- 3
- Pages
- 211-240
- ISSN
- 0033-5835 (ISSN-L)
- 1469-8994
- OpenAlex
- W2127375496
- Cited by
- 229
- References
- 2
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NMR-based screening in drug discovery. https://app.cochat.ai/papers/10.1017/s0033583500003528
- The paper
- Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1999). NMR-based screening in drug discovery. Quarterly Reviews of Biophysics. https://doi.org/10.1017/s0033583500003528
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.